Restricted accessResearch articleFirst published online 2011-11
The administration of psilocybin to healthy,hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability
This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the viability of functional magnetic resonance imaging work with psilocybin.
DittrichA (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry31(Suppl. 2): 80–84.
2.
Gouzoulis-MayfrankESchreckenbergerMSabriO (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F] FDG. Neuropsychopharmacology20: 565–581.
3.
GriffithsRRRichardsWAMcCannUJesseR (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl)187: 268–283.
4.
GrinspoonLBakalarJB (1979) Psychedelic drugs reconsidered. New York: Basic Books.
5.
HaslerFBourquinDBrenneisenRBärTVollenweiderFX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv72: 175–184.
6.
HaslerFGrimbergUBenzMAHuberTVollenweiderFX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a doubleblind, placebo-controlled dose-effect study. Psychopharmacology (Berl)172: 145–156.
7.
HofmannAFreyAOttHPetr-ZilkerTTroxlerF (1958) Elucidation of the structure and the synthesis of psilocybin. Experientia14: 397–399.
8.
HofmannAHeimRBarckA (1959) Psilocybin and psilocin. Helv Chim Acta42: 1557–1572.
9.
JohnsonMRichardsWGriffithsR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol22: 603–620.
10.
LeeAAShlainB (1985) Acid dreams. The complete social history of LSD. New York: Grove Press.
11.
LeunerH (1963) Psychotherapy with hallucinogens. A clinical report with special reference to the revival of emotional phases of childhood. In: CrockettRSandisonRWalkAHallucinogenic drugs and their psychotherapeutic useLondon: H.K.Lewis67–73.
OsmondH (1957) A review of the clinical effects of psychotomimetic Agents. Ann N Y Acad Sci66: 418–434.
14.
SpencerAM (1966) Lysergic acid diethylamide. Br Med J2: 49–49.
15.
VollenweiderFXLeendersKLScharfetterCMaguirePStadelmannOAngstJ (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology16: 357–372.
